Bioxytran (BIXT) Other Non Operating Income (2012 - 2026)
Bioxytran (BIXT) posted Other Non Operating Income of -$73136.0 for Q1 2026, down 561.34% sequentially from $15853.0 in Q4 2025, and up 90.91% YoY from -$38308.8 in Q1 2025.
Bioxytran (BIXT) Other Non Operating Income (2012 - 2026) Analysis & Trends
Bioxytran has reported Other Non Operating Income for 9 years, with the latest figure at -$73136.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 90.91% year-over-year to -$73136.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $514915.0 (up 170.38% YoY) and the FY2025 annual result came in at -$216701.0, down 262.78% from the prior year.
- Other Non Operating Income eased to -$73136.0 in Q1 2026 per BIXT's latest filing, from $15853.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $307402.0 in Q2 2025 and troughed at -$804752.0 in Q1 2025.
- A 4-year average of -$27089.9 and a median of -$15158.5 in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 673.52% in 2025, down 93.94% in 2025.
- Over 4 years, Other Non Operating Income stood at -$142190.0 in 2023, then soared by 283.89% to $261478.0 in 2024, then plunged by 93.94% to $15853.0 in 2025, then sank by 561.34% to -$73136.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$73136.0, $15853.0, and $264796.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73,136.00 |
| Dec 31, 2025 | 15,853.00 |
| Sep 30, 2025 | 264,796.00 |
| Jun 30, 2025 | 307,402.00 |
| Mar 31, 2025 | -804,752.00 |
| Dec 31, 2024 | 261,478.00 |
| Sep 30, 2024 | -46,170.00 |
| Sep 30, 2023 | -142,190.00 |
| Jun 30, 2018 | -3,050.00 |
| Mar 31, 2018 | -1,950.00 |
| Jun 30, 2017 | -1,950.00 |
| Mar 31, 2017 | -1,950.00 |
| Mar 31, 2015 | 75.00 |
| Dec 31, 2014 | 4,652.00 |
| Mar 31, 2014 | 348.00 |
| Sep 30, 2012 | -200.00 |
| Jun 30, 2012 | 200.00 |
| Mar 31, 2012 | 10,000.00 |